BRONCHOPULMONARY DYSPLASIA: TREATMENT AND PREVENTION
DOI:
https://doi.org/10.46793/PP160813002CKeywords:
bronchopulmonary dysplasia, prematurity, reviewAbstract
Since 1967, when it was first defined and described the nature and definition of bronchopulmonary dysplasia (BPD) has evolved. Based on clinical and radiographic evidence of pulmonary disease in moderately to late premature infants with a history of respiratory distress syndrome, BPD was familiarly defined as a chronic form of lung disease in neonates treated with oxygen and positive pressure ventilation for a primary lung disorder, the nature of BPD has evolved into a “new” form of BPD typically seen in neonates surviving at the threshold of viability and characterized primarily by arrest of alveolar and vascular development. Infants develop BPD in about 1.5% of all newborn births. The incidence of BPD appears to be growing in conjunction with the increased survival of very-low-birth-weight infants who are treated for and recover from respiratory distress syndrome (RDS). This review has been an up-date of literature data, including animal studies, human pilot studies, randomized controlled trials (RCTs), meta-analyses and systematic reviews published on the PubMed data base.
References
Northway WH, Rosan RC, Porter DY. Pulmonary Disease Following Respirator Therapy of Hyaline-Membrane Disease. NEJM 1967; 276:357–368.
Husain AN, Siddiqui NH and Stocker JT. Pathology of development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29: 710–717. doi:10.1016/S0046-8177(98)90280-5
Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999; 46:641–643. doi:10.1203/00006450-199912000-00007
Jobe AH and Bancalari.Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723–1729.doi:10.1164/ajrccm.163.7.2011060
Baraldi E and Filippone M. Chronic lung disease after premature birth. NEJM 2007; 357: 1946–1955.doi:10.1056/NEJMra067279
Cerny L, Torda JS, Rehan VK. Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook. Lung 2008;186(2):75-89.
Tin W, Wiswell TE. Adjunctive therapies in chronic lung disease: examining the evidence. Semin Fetal Neonatal Med 2008;13(1)44- 52.
Ambalavanan N, Carlo W. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006;30(4):192-199.
Rush MG, Engelhardt B, Parker RA and Hazinski TA. Double- blind, placebo-controlled trial of alternate day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr 1990; 117: 112–118.doi: 10.1016/S0022-3476(05)82458-8
Sahni J and Phelps S. Nebulized furosemide in the treatment of bron- chopulmonary dysplasia in preterm infants. J Pediatr Pharmacol Ther 2011; 16: 14–22. doi: 10.1002/14651858.CD001453
Stewart A and Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Data base Syst Rev 2011; 9:CD001453. doi:10.1002/14651858.CD001453.pub2
Segar JL. Neonatal diuretic therapy: furosemide, thiazides and spironolactone. Clin Perinatol 2012; 39: 209–220.doi:10.1016/j.clp.2011.12.007
Hoffman DJ, Gerdes JS and Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease:a double-blind, placebo-controlled randomized trial. J Perinatol 2000; 20, 41–45.doi:10.1038/sj.jp.7200307.
Robin B, Kim Y J, Huth J, Klocksieben J, Torres M, Tepper RS et al. Pulmonary function in bronchopulmonary dysplasia. Pediat Pulmonol 2004; 37: 236–242.doi:10.1002/ppul.10424
Ng G, Da Silva O and Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2012;6:CD003214. doi:10.1002/14651858.CD003214.pub2
De Boeck K, Smith J, Van Lierde S and Devlieger H.Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. Eur J Pediatr 1998; 157, 75–79.doi:10.1007/s004310050771
Pantalitschka T and Poets CF. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia. Pediatr Pulmonol 2006; 41: 703–708.doi: 10.1002/ppul.20467
Ghanta S, Leeman KT and Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 115–123.doi: 10.1053/j.semperi.2013.01.008
Schmidt B, Roberts RS, Davis P, Doyle L, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. NEJM 2006; 354: 2112–2121. doi:10.1056/NEJMoa054065
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Long-term effects of caffeine therapy for apnea of prematurity. NEJM 2007;357, 1893–1902.doi:10.1056/NEJMoa073679
Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asz- talos EV,et al. Survival without disability to age 5years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307: 275–282.doi: 10.1001/jama.2011.2024
Anzano MA, Olson JA and Lamb AJ.Morphologic alterations in the trachea and the salivary gland following the induction of rapid synchronous vitamin A deficiency in rats. Am J Pathol.1980; 98: 717–732.
Shenai JP, Rush MG, Stahlman MT and Chytil F. Plasmaretinol- binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. J. Pediatr.1990; 116: 607–614.doi:10.1016/S0022- 3476(05)81614-2
Darlow BA and Graham PJ.Vitamin A supplementation to prevent mortality and short-and long-term morbidity in very low birth weight infants. Cochrane Data base Syst Rev 2011; 10:CD000501. doi: 10.1002/14651858.CD000501.pub3
Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998; Apr 16. 338(16):1112-8.
Onland W, Offringa M and van Kaam A. Late (≥7 days) inhalation cor- ticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst.Rev.2012; 4:CD002311
Shah VS, Ohlsson A, Halliday HL and Dunn M. Early administration of inhaled corticosteroids for preventing chronic lungdisease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2012; 5:CD001969. doi: 10.1002/14651858.CD001969.pub3
Shah SS, Ohlsson A, Halliday HL and ShahVS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2012;. 5:CD002058. doi: 10.1002/14651858.CD002058.pub2
Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC et al.Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120, 1260–1269.doi:10.1542/peds.2007-0971
Steinhorn RH.Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev 2013; 89, 865–874.doi:10.1016/j.earlhumdev.2013.09.012
MacRitchie AN, Albertine KH, Sun J, Lei PS, Jensen SC, Freestone AA et al.Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol 2001; 281, L1011– L1020.
Afshar S, Gibson LL, Yuhanna IS, Sherman TS, Kerecman JD, Grubb PH et al. Pulmonary NO synthase expression isattenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 284, L749–L758.
Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill, JD et al. NOCLD Study Group.Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. NEJM 2006; 355, 343–353.doi: 10.1056/NEJMoa061088
Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK et al. Inhaled nitric oxide for premature infants with severe respiratory failure. NEJM 2005; 353, 13–22.doi: 10.1056/NEJMoa043927
Askie LM, Ballard RM, Cutter GR, Dani C, Elbourne D, Field D. et al. Inhaled nitric oxide in preterm infants: an individual patient-data meta- analysis of randomized trials. Pediatrics 2011; 128, 729–739.doi:10.1542/peds.2010- 2725
Donahue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127, e414–e422.doi:10.1542/peds.2010-3428
Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics.2008;121(2):419–432pmid:18245434
Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD001149pmid:10796417
Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome.Cochrane Database Syst Rev 2009; (2):CD007836pmid:19370695
Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001;
( 2):CD000144pmid:11405951
Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012;3(3):CD000510pmid:22419276
Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007;(4):CD003063pmid:17943779
Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2012;11(11):CD001456pmid:23152207
Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010; (1):CD001079pmid:20091513
Pfister RH, Soll R, Wiswell TE. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst
Rev. 2009; (4):CD006180pmid:19821357
Soll R, Ozek E Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2009; (1):CD000141pmid:19160177
Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2):CD000511pmid:10796380
